Acquisition of Resistance to Fas-mediated Apoptosis by Overexpression of Clusterin in Human Renal-cell Carcinoma Cells
Overview
Authors
Affiliations
Recent studies have shown the antiapoptotic activity of clusterin against a wide variety of stimuli; however, the functional role of clusterin in Fas-mediated apoptosis has not been well characterized. We transfected the clusterin cDNA into human renal-cell carcinoma (RCC) ACHN cells that scarcely express clusterin protein in order to examine whether overexpression of clusterin inhibits the Fas-mediated signal pathway for apoptotic cell death. No significant difference was observed in the in vitro cell growth rates between the clusterin-transfected cell line (ACHN/CL) and the vector-only-transfected control cell line (ACHN/C), whereas the colony-forming efficiency in soft agar of ACHN/CL was significantly higher than that of ACHAN/C. The anti-Fas monoclonal antibody CH11 induced apoptosis in ACHAN/C cells in a dose-dependent manner; however, the growth-inhibitory effect of CH11 on ACHN/CL cells was markedly suppressed, with corresponding increases in p53 expression and decrease in the fraction of cells in the sub-G(1) phase of the cell cycle. Furthermore, the cytotoxic effect of CH11 on ACHN/CL cells was augmented by treatment with interferon-gamma, but a corresponding effect on ACHN/C cells was not observed. These findings suggest that overexpression of clusterin may contribute to a phenotype resistant to Fas-mediated apoptosis, and that if interferon-gamma treatment is added according to the clusterin expression level, Fas-mediated therapy could be a novel approach to RCC.
HMGB1 induction of clusterin creates a chemoresistant niche in human prostate tumor cells.
Zhou J, Chen X, Gilvary D, Tejera M, Eksioglu E, Wei S Sci Rep. 2015; 5:15085.
PMID: 26469759 PMC: 4606829. DOI: 10.1038/srep15085.
Hepatitis D and hepatocellular carcinoma.
Abbas Z, Abbas M, Abbas S, Shazi L World J Hepatol. 2015; 7(5):777-86.
PMID: 25914778 PMC: 4404383. DOI: 10.4254/wjh.v7.i5.777.
Lamoureux F, Baudhuin M, Ory B, Guiho R, Zoubeidi A, Gleave M Oncotarget. 2014; 5(17):7805-19.
PMID: 25138053 PMC: 4202162. DOI: 10.18632/oncotarget.2308.
Clusterin: a key player in cancer chemoresistance and its inhibition.
Koltai T Onco Targets Ther. 2014; 7:447-56.
PMID: 24672247 PMC: 3964162. DOI: 10.2147/OTT.S58622.
Blumenstein B, Saad F, Hotte S, Chi K, Eigl B, Gleave M Cancer Med. 2013; 2(4):468-77.
PMID: 24156019 PMC: 3799281. DOI: 10.1002/cam4.93.